Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-6148
Authors: Piepgras, Johannes
Müller, Aneka
Falk, Steffen
Lotz, Johannes
Loquai, Carmen
Zipp, Frauke
Dresel, Christian
Bittner, Stefan
Title: Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody–positive autoimmune encephalitis under immune checkpoint inhibitor therapy
Online publication date: 2-Jul-2021
Language: english
Abstract: Neurological immune-mediated side effects are rare but often severe complications of immune checkpoint inhibitor (ICI) treatment. This report describes a severe case of nivolumab/ipilimumab-associated glutamic acid decarboxylase 65–positive autoimmune encephalitis. It proposes neurofilament light chain levels, a biomarker indicating axonal damage, in the cerebrospinal fluid and serum as a putative novel biomarker for this diagnostically and therapeutically challenging entity with an often unfavorable outcome. Additionally, we provide an overview of previous reports of patients developing autoimmune encephalitis under ICI treatment.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-6148
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY-NC
Information on rights of use: https://creativecommons.org/licenses/by-nc/4.0/
Journal: European journal of neurology
28
3
Pages or article number: 1086
1089
Publisher: Wiley-Blackwell
Publisher place: Oxford u.a.
Issue date: 2021
ISSN: 1468-1331
Publisher URL: https://doi.org/10.1111/ene.14692
Publisher DOI: 10.1111/ene.14692
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
piepgras_johannes-neurofilament_-20210702103931357.pdf376.93 kBAdobe PDFView/Open